Amarin Corporation

Amarin Corporation Gross Margin

The Gross Margin of Amarin Corporation (AMRN) as of Nov 5, 2026 is 56.57 %. In the previous year, Gross Margin was 35.60 % — a change of 58.92% (higher).

Gross Margin

56.57 %

YoY

58.92%

Last updated:

Gross Margin of Amarin Corporation is 2025 56.57 % . Gross Margin of Amarin Corporation was 2024 35.60 % . It decreases by 58.92% higher compared to the previous year.

Amarin Corporation's gross margin stands at 56.6%, down from 79.2% several years earlier.

The Amarin Corporation Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
76.20 USD
Jan 1, 2019
77.66 USD
Jan 1, 2020
78.59 USD
Jan 1, 2021
79.20 USD
Jan 1, 2022
65.68 USD
Jan 1, 2023
53.94 USD
Jan 1, 2024
35.60 USD
Jan 1, 2025
56.57 USD
The Amarin Corporation Gross Margin history
YEARGross MarginYoY
56.57 %+58.92%
35.60 %-34.00%
53.94 %-17.88%
65.68 %-17.07%
79.20 %+0.77%
78.59 %+1.21%
77.66 %+1.91%
76.20 %+1.36%
75.18 %+2.17%
73.58 %+11.65%
65.90 %+5.95%
62.21 %+11,252.55%
0.55 %-45.21%
1.00 %0.00%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Gross Margin of Amarin Corporation is 56.57 % in 2025.

Gross Margin of Amarin Corporation changed from 35.60 % to 56.57 %, representing a 58.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Amarin Corporation

All Key Metrics — Amarin Corporation